Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA): 9 pipeline candidates · 3 upcoming catalysts · ~27 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
26.6 months
D/E 12.24 · 0% dilution
Lead: Approved
9 candidates
3 upcoming, next in ~44d
1 buy · 15 sells (180d)
A transparent, data-derived signal for Akebia Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$257.6M
Cash
$164.3M
Quarterly Burn
$21.2M
Runway
26.6 mo
Revenue
$53.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| AKB-097 | Phase 2 |
| AKB-10108 | Phase 1 |
| AKB-9090 | Phase 1 |
| Auryxia | Phase 3 |
| Erythropoiesis-Stimulating Agent | Phase 3 |
| ferric citrate | Phase 3 |
| praliciguat | Phase 2 |
| Vadadustat | Phase 3 |
| Vafseo | Approved |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
170
Total value held
$150.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 22,333,420 | $31.0M |
| blackrock, inc. | 18,693,296 | $26.0M |
| state street corp | 11,614,006 | $16.1M |
| geode capital management, llc | 6,452,252 | $9.0M |
| goldman sachs group inc | 3,602,827 | $5.0M |
| citigroup inc | 2,854,586 | $4.0M |
| bank of america corp /de/ | 2,763,362 | $3.8M |
| millennium management llc | 2,384,713 | $3.3M |
| vanguard portfolio management llc | 2,215,441 | $3.1M |
| charles schwab investment management inc | 2,015,577 | $2.8M |
Showing top 10 of 170 institutional holders of Akebia Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Akebia Therapeutics, Inc.'s pipeline?
Akebia Therapeutics, Inc. (AKBA) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Akebia Therapeutics, Inc.'s lead drug candidate?
Akebia Therapeutics, Inc.'s most advanced tracked candidate is AKB-097 (Phase 2) for Planned evaluation in complement-mediated kidney diseases including C3 Glomerulopathy (C3G), IgA Nephropathy (IgAN) and Lupus Nephritis (LN)..
What is Akebia Therapeutics, Inc.'s next catalyst?
Akebia Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada" — expected August 1, 2026.
What is Akebia Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Akebia Therapeutics, Inc. has approximately 26.6 months of cash runway.
What is Akebia Therapeutics, Inc.'s market capitalization?
Akebia Therapeutics, Inc.'s market capitalization is approximately $257.6M.
Get the full picture on Akebia Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.